ArticleMolecular therapy : the journal of the American Society of Gene Therapy2008
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Magnetic hyperthermia therapy enhances the chemoradiosensitivity of glioblastoma.Scientific reports · 2025Article
- Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery.World neurosurgery · 2025Review
- Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy.CNS oncology · 2019Review
- Current Options and Future Directions in Immune Therapy for Glioblastoma.Frontiers in oncology · 2018Review
- Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging.Journal of biomedical nanotechnology · 2015Review
- Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.Journal of neuro-oncology · 2015Article
- Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.Therapeutic delivery · 2015Review
- The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.Frontiers in microbiology · 2014Review
- Article
- Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.Oncolytic virotherapy · 2013Review
- Magnetic nanoparticles and their applications in image-guided drug delivery.Drug delivery and translational research · 2012Article
- Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy.Theranostics · 2012Article
- Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.Cancer gene therapy · 2011Article
- EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.Cancer research · 2010Article
- Herpesvirus vectors for therapy of brain tumors.The open virology journal · 2010Article
- Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Future oncology (London, England) · 2010Review
- Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.Molecular cancer therapeutics · 2010Article
- Convection-enhanced delivery for the treatment of brain tumors.Expert review of neurotherapeutics · 2009Review
- Oncolytic viral therapy of malignant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The herpes simplex virus-1 (HSV-1)-infected cell protein 0 (ICP0) is an E3 ubiquitin ligase implicated in cell cycle arrest and DNA repair inhibition. Convection-enhanced delivery (CED) of either the replication-defective, ICP0-producing HSV-1 mutant, d106, or the recombinant d109, devoid of all viral genome expression, was performed to determine the in vivo efficacy of ICP0 in combination with ionizing radiation (IR) or systemic temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM). Intracranial U87-MG xenografts were established in athymic nude mice. Animal survival was determined after mice underwent intracranial CED of either the replication-defective d106 or d109 viruses, or Hanks' balanced salt solution (HBSS), before a single session of whole-brain irradiation or TMZ treatment. Median survival for animals that underwent treatment with HBSS alone, d109 alone, d106 alone, HBSS + IR, HBSS + TMZ, d109 + IR, d106 + IR, and d106 + TMZ was 28, 35, 41, 39, 44, 39, 68 (P < 0.01), and 66 days (P < 0.01), respectively. Intracerebral d106 CED resulted in a significant increase in athymic nude mouse survival when combined with IR or TMZ. d106 CED allows for distribution of HSV-1 in human GBM xenografts and persistent viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.